<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Design Therapeutics</title>
    <link>https://www.biospace.com/employer/3076401/design-therapeutics</link>
    <description>Design Therapeutics</description>
    <language>en-US</language>
    <lastBuildDate>Fri, 20 Mar 2020 11:36:05 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/3076401/design-therapeutics.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Design Therapeutics Launches with $45 Million to Develop a New Class of Disease-Modifying Therapies for Serious Degenerative Disorders</title>
      <link>https://www.biospace.com/design-therapeutics-launches-with-45-million-to-develop-a-new-class-of-disease-modifying-therapies-for-serious-degenerative-disorders</link>
      <description>March 20, 2020 12:30 UTC Series A Financing Funds Novel Pipeline for Patients with Nucleotide Repeat Disorders Company Advancing Lead Program for Friedreich’s Ataxia toward Clinical Development SAN DIEGO--( BUSINESS WIRE )-- Design Therapeutics announced today that it is launching to create and develop a new class of therapies for patients with serious degenerative disorders caused by nucleotide repeat expansions. The company has closed a $45 million Series A fina</description>
      <pubDate>Fri, 20 Mar 2020 11:36:05 GMT</pubDate>
      <guid>https://www.biospace.com/design-therapeutics-launches-with-45-million-to-develop-a-new-class-of-disease-modifying-therapies-for-serious-degenerative-disorders</guid>
    </item>
    <item>
      <title>Design Therapeutics Appoints Industry Veteran, Dr. João Siffert, as Chief Executive Officer</title>
      <link>https://www.biospace.com/design-therapeutics-appoints-industry-veteran-dr-joao-siffert-as-chief-executive-officer</link>
      <description>Design Therapeutics, a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by nucleotide repeat expansions, today announced that João Siffert, M.D., has been appointed as</description>
      <pubDate>Tue, 20 Oct 2020 12:36:12 GMT</pubDate>
      <guid>https://www.biospace.com/design-therapeutics-appoints-industry-veteran-dr-joao-siffert-as-chief-executive-officer</guid>
    </item>
    <item>
      <title>Design Therapeutics Secures $125 Million in Series B Financing to Advance Pipeline of Genomic Medicines for Nucleotide Repeat Expansion Disorders</title>
      <link>https://www.biospace.com/design-therapeutics-secures-125-million-in-series-b-financing-to-advance-pipeline-of-genomic-medicines-for-nucleotide-repeat-expansion-disorders</link>
      <description>Design Therapeutics, a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, today announced the successful completion of a $125 million Series B financing, led by Logos Capital.</description>
      <pubDate>Wed, 27 Jan 2021 13:36:06 GMT</pubDate>
      <guid>https://www.biospace.com/design-therapeutics-secures-125-million-in-series-b-financing-to-advance-pipeline-of-genomic-medicines-for-nucleotide-repeat-expansion-disorders</guid>
    </item>
    <item>
      <title>Design Therapeutics Announces Pricing of Initial Public Offering - Mar 26, 2021</title>
      <link>https://www.biospace.com/design-therapeutics-announces-pricing-of-initial-public-offering-mar-26-2021</link>
      <description>Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price to the public of $20.00 per share.</description>
      <pubDate>Fri, 26 Mar 2021 02:56:07 GMT</pubDate>
      <guid>https://www.biospace.com/design-therapeutics-announces-pricing-of-initial-public-offering-mar-26-2021</guid>
    </item>
    <item>
      <title>Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
      <link>https://www.biospace.com/design-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares</link>
      <description>Design Therapeutics, Inc. (Nasdaq: DSGN) (“Design”), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, today announced the closing of its previously announced initial public offering of 13,800,000 shares of its common stock,</description>
      <pubDate>Tue, 30 Mar 2021 20:06:07 GMT</pubDate>
      <guid>https://www.biospace.com/design-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares</guid>
    </item>
    <item>
      <title>Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results</title>
      <link>https://www.biospace.com/design-therapeutics-announces-business-highlights-and-reports-first-quarter-2021-financial-results</link>
      <description>Successful $276 Million IPO Completed to Advance GeneTACTM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development</description>
      <pubDate>Mon, 10 May 2021 20:06:08 GMT</pubDate>
      <guid>https://www.biospace.com/design-therapeutics-announces-business-highlights-and-reports-first-quarter-2021-financial-results</guid>
    </item>
    <item>
      <title>Design Therapeutics Expands Board of Directors with Key Appointments</title>
      <link>https://www.biospace.com/design-therapeutics-expands-board-of-directors-with-key-appointments</link>
      <description>Design Therapeutics, Inc. (Nasdaq: DSGN), today announced the appointments of industry veterans, Heather Behanna, Ph.D., principal of SR One, and Deepa Prasad, managing director of WestRiver Group, to its board of directors effective June 15, 2021.</description>
      <pubDate>Mon, 07 Jun 2021 20:06:04 GMT</pubDate>
      <guid>https://www.biospace.com/design-therapeutics-expands-board-of-directors-with-key-appointments</guid>
    </item>
    <item>
      <title>Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference</title>
      <link>https://www.biospace.com/design-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference</link>
      <description>Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João Siffert, M.D., president and chief executive officer, will participate in a fireside chat during the Goldman Sachs 42nd Annual Global Healthcare Conference</description>
      <pubDate>Mon, 07 Jun 2021 20:16:05 GMT</pubDate>
      <guid>https://www.biospace.com/design-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference</guid>
    </item>
    <item>
      <title>Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results</title>
      <link>https://www.biospace.com/design-therapeutics-reports-genetac-portfolio-progress-and-second-quarter-2021-results</link>
      <description>Design Therapeutics, Inc., a biotechnology company developing treatments for degenerative genetic disorders, reported recent progress with its portfolio of novel small molecule gene targeted chimeras, as well as business highlights and second quarter 2021 financial results.</description>
      <pubDate>Mon, 09 Aug 2021 20:06:06 GMT</pubDate>
      <guid>https://www.biospace.com/design-therapeutics-reports-genetac-portfolio-progress-and-second-quarter-2021-results</guid>
    </item>
    <item>
      <title>Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1</title>
      <link>https://www.biospace.com/design-therapeutics-announces-positive-preclinical-data-highlighting-disease-modifying-potential-of-its-novel-dm1-genetacs-as-a-treatment-for-myotonic-dystrophy-type-1</link>
      <description>Design Therapeutics, Inc., a biotechnology company developing small molecule treatments for degenerative genetic disorders, announced new preclinical data from its novel DM1 GeneTAC™ program, which demonstrated a near-complete resolution of disease-causing foci and correction of splicing defects in myotonic dystrophy type-1 patient cells.</description>
      <pubDate>Wed, 08 Sep 2021 10:36:05 GMT</pubDate>
      <guid>https://www.biospace.com/design-therapeutics-announces-positive-preclinical-data-highlighting-disease-modifying-potential-of-its-novel-dm1-genetacs-as-a-treatment-for-myotonic-dystrophy-type-1</guid>
    </item>
  </channel>
</rss>
